The doors to Eli Lilly and Company’s new biotechnology development campus were opened to attendees of the recent “Labs21” conference, which focused on sustainable solutions for new and renovated R&D facilities.
Sustainable laboratory design can spark interest in scientific inquiry, help companies attract scientists looking for an employer with a social and environmental conscience, and provide a safe and efficient work environment, according to John Lechleiter, Ph.D., chairman, president, and CEO of Lilly.
Lilly’s environmental efforts between 2003 and 2007 have reportedly yielded a 50% decrease in hazardous material purchases and a 2.4% reduction in absolute energy use. Greenhouse gas emissions and volatile emissions were also reduced by 33% and 40%, respectively.
The new biotech development campus, known as Building 362, is situated on the firm’s corporate campus in Indianapolis where Lilly makes bioproducts such as teriparatide (Fortéo™) for osteoporosis, drotrecogin alfa (Xigris®) for sepsis, somatropin (Humatrope®) for growth disorders, and human insulin (Humulin®), exenatide (Byetta®), and insulin lispro (Humalog®) for diabetes.
The campus encompasses the 477,500-sq-ft R&D building, a 180,000-sq-ft GMP pilot-plant facility, and an administration building. Activities supported in the development facility include mammalian cell and yeast culture of recombinant DNA based biopharmaceuticals, cell banking, isolation and purification operations, analytical and biophysical characterization studies, drug formulation, and fill/finish operations.
One of the concepts underlying the campus design was to bring the people who work in these various R&D areas in closer proximity to foster collaborative opportunities. The development facility took two years to plan and three years to build. Chris Harp, representing Flad Architects, said that 300 design engineers worked on the project for a total of 200,000 man-hours. Construction required 1.7 million man-hours and the joint effort of 3,000 craftspersons.